BPC-157 vs Epitalon
Overview
BPC-157 is primarily a healing & recovery peptide, while Epitalon is used for anti-aging & longevity.
This page compares BPC-157 and Epitalon across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| BPC-157 | Epitalon | |
|---|---|---|
| Category | Healing & Recovery | Anti-aging & Longevity |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | Compounding (Rx) — Apr 2026 |
| Typical dosage | 250-500 mcg | 5-10 mg |
| Frequency | daily | cycle |
| Reported benefits | Accelerated wound healing, tendon and ligament repair, gut health improvement, reduced inflammation, neuroprotective effects | Areas studied (research-reported, not established efficacy): telomerase activation and telomere elongation in human cell lines (PMID 12937682; DOI 10.1007/s10522-025-10315-x); increased melatonin synthesis and circadian effects in a small human study; lower overall and cardiovascular mortality in a 12-15 year single-lab trial that used pineal extract (epithalamin), not synthetic AEDG (PMID 17426848, 22451889). No independent multi-center RCTs; not FDA-approved. |
| Reported side effects | Generally well-tolerated. Rare: injection site reactions, mild fatigue | Khavinson-group trials reported no serious adverse events (e.g., n=162 retinitis pigmentosa trial, PMID 12195242), but these are the only controlled safety data and remain unreplicated. Community use reports mild injection-site reactions. Theoretical concern: telomerase activation is a hallmark of most cancers, and a 2025 review (PMC11943447) notes carcinogenic potential is unstudied. No human pharmacokinetic or drug-interaction data. |
Key differences
Primary use. BPC-157 is categorised under Healing & Recovery, while Epitalon falls under Anti-aging & Longevity. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Epitalon: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Epitalon is typically dosed at 5-10 mg (cycle).
Can you stack them?
Some protocols combine peptides, but stacking BPC-157 and Epitalon has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between BPC-157 and Epitalon?
- BPC-157 is primarily a healing & recovery peptide, while Epitalon is used for anti-aging & longevity. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is BPC-157 used for?
- Healing & recovery, gut health.
- What is Epitalon used for?
- Longevity, telomere support.
- Can you take BPC-157 and Epitalon together?
- Some users combine peptides within a single protocol, but stacking BPC-157 and Epitalon has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is BPC-157 or Epitalon FDA-approved?
- BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Epitalon is not FDA-approved; compounding permitted with a prescription (as of April 2026).